Merck (MRK) Intangibles (2009 - 2026)
Merck (MRK) reported Intangibles of $25.7 billion for Q1 2026, up 63.38% year-over-year from $15.8 billion in Q1 2025, and down 3.51% quarter-over-quarter from $26.7 billion in Q4 2025.
Merck (MRK) Intangibles (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of Intangibles data on file, last reported at $25.7 billion in Q1 2026.
- Intangibles for Q1 2026 came in at $25.7 billion, up 63.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.7 billion (up 63.38% YoY), and the FY2025 annual result was $26.7 billion, up 62.99% from the prior year.
- Intangibles eased to $25.7 billion in Q1 2026 per MRK's latest filing, from $26.7 billion in the prior quarter.
- Over five years, Intangibles peaked at $26.7 billion in Q4 2025 and troughed at $15.2 billion in Q2 2025.
- A 5-year average of $19.4 billion and a median of $19.2 billion in 2023 frame the typical range for Intangibles.
- The sharpest annual moves came in 2022 and 2023: Intangibles soared 65.15% in 2022, then retreated 13.75% in 2023.
- A 5-year view of Intangibles shows it stood at $20.3 billion in 2022, then decreased by 11.14% to $18.0 billion in 2023, then fell by 9.11% to $16.4 billion in 2024, then jumped by 62.99% to $26.7 billion in 2025, then dropped by 3.51% to $25.7 billion in 2026.
- Business Quant data shows MRK's Intangibles at $25.7 billion in Q1 2026, $26.7 billion in Q4 2025, and $15.3 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 24.45 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 7.37 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 49.06 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 50.87 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 25.75 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 21.38 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 16.38 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 52.56 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 18.24 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | 10.60 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.75 Bn |
| Dec 31, 2025 | 26.68 Bn |
| Sep 30, 2025 | 15.31 Bn |
| Jun 30, 2025 | 15.19 Bn |
| Mar 31, 2025 | 15.76 Bn |
| Dec 31, 2024 | 16.37 Bn |
| Sep 30, 2024 | 17.01 Bn |
| Jun 30, 2024 | 16.98 Bn |
| Mar 31, 2024 | 17.57 Bn |
| Dec 31, 2023 | 18.01 Bn |
| Sep 30, 2023 | 19.20 Bn |
| Jun 30, 2023 | 19.67 Bn |
| Mar 31, 2023 | 19.86 Bn |
| Dec 31, 2022 | 20.27 Bn |
| Sep 30, 2022 | 21.37 Bn |
| Jun 30, 2022 | 22.50 Bn |
| Mar 31, 2022 | 23.02 Bn |
| Dec 31, 2021 | 22.93 Bn |
| Sep 30, 2021 | 13.38 Bn |
| Jun 30, 2021 | 13.62 Bn |